How to measure pharmacokinetics in critically ill patients?

Current Pharmaceutical Biotechnology

Volumn 12, Issue 12, 2011, Pages 2037-2043

  Liu, Xin ^a   Kruger, Peter S ^a,b   Roberts, Michael S ^a,c  

^a UNIVERSITY OF QUEENSLAND   (Australia)

^b PRINCESS ALEXANDRA HOSPITAL   (Australia)

^c UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Critically ill patient; Microdialysis; Pharmacodynamics; Physiology; Population pharmacokinetics; Therapeutic drug monitoring

Indexed keywords

AMINOGLYCOSIDE ANTIBIOTIC AGENT; POLYPEPTIDE ANTIBIOTIC AGENT;

ANALYTIC METHOD; ARTICLE; BLOOD SAMPLING; CRITICALLY ILL PATIENT; DATA ANALYSIS; DRUG ADMINISTRATION; DRUG BLOOD LEVEL; DRUG CLASSIFICATION; DRUG DOSE REGIMEN; DRUG MONITORING; EXTRACELLULAR FLUID; HUMAN; INTENSIVE CARE UNIT; MEDICAL ETHICS; MEDICAL LITERATURE; MICRODIALYSIS; PHARMACOKINETICS; PLASMA VOLUME; TISSUE DISTRIBUTION;

CRITICAL ILLNESS; HUMANS; PHARMACEUTICAL PREPARATIONS; PHARMACOKINETICS;

EID: 84555200648     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920111798808239     Document Type: Article

References (51)

1. Pea, F.; Viale, P.; Furlanut, M. Antimicrobial therapy in critically ill patients: a review of pathophysiological conditions responsible for altered disposition and pharmacokinetic variability. Clin. Pharmacokinet, 2005, 44(10), 1009-1034.
2. Boucher, B.A.; Wood, G.C.; Swanson, J.M. Pharmacokinetic changes in critical illness. Crit. Care Clin., 2006, 22(2), 255-271.
3. Roberts, J.A.; Lipman, J. Antibacterial dosing in intensive care: pharmacokinetics, degree of disease and pharmacodynamics of sepsis. Clin. Pharmacokinet, 2006, 45(8), 755-773.
4. Liu, X.; Kruger, P.; Roberts, M.S. In: 2009 Yearbook of Intensive Care and Emergency Medicine, Vincent, J.L., Ed. Springer: New York, 2009; pp. 859-869.
5. Roberts, J.A.; Lipman, J. (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit. Care Med. 2009, 37(3), 840-851.
6. Udy, A.A.; Roberts, J.A.; Boots, R.J.; Paterson, D.L.; Lipman, J. Augmented renal clearance: implications for antibacterial dosing in the critically ill. Clin. Pharmacokinet, 2010, 49(1), 1-16.
7. Park, G.R. Pharmacokinetics and pharmacodynamics in the critically ill patient. Xenobiotica. 1993, 23(11), 1195-1230.
8. Chan, S.; Gerson, B. Clin. Lab. Med., 19877(2), 279-287.
9. Soldin, S.J. Free drug monitoring. Arch. Pathol. Lab. Med., 1999, 123(9), 822-823.
10. Pea, F.; Pavan, F.; Furlanut, M. Clinical relevance of pharmacokinetics and pharmacodynamics in cardiac critical care patients. Clin. Pharmacokinet, 2008, 47(7), 449-462.
11. Drusano, G.L.; Forrest, A.; Snyder, M.J.; Reed, M.D.; Blumer, J.L. An evaluation of optimal sampling strategy and adaptive study design. Clin. Pharmacol. Ther., 1988, 44(2), 232-238.
12. Yuen, G.J.; Drusano, G.L.; Forrest, A.; Plaisance, K.; Caplan, E.S. Prospective use of optimal sampling theory: steady-state ciprofloxacin pharmacokinetics in critically ill trauma patients. Clin. Pharmacol. Ther., 1989, 46, 451-457.
13. Miyazaki, M.; Oguri, T.; Kurata, T.; Takahashi, T.; Daga, H.; Fujitaka, K.; Isobe, T.; Nakajima, M.; Fujiwara, Y.; Kohno, N. Validation of the limited-sampling models for carboplatin AUC in combination chemotherapy with taxanes. Anticancer Res., 2004, 24(3b), 1911-1914.
14. Reed, M.D. Optimal sampling theory: An overview of its application to pharmacokinetic studies in infants and children. Pediatrics, 1999, 104(3 Pt 2), 627-632.
15. Begg, E.J.; Barclay, M.L., Duffull, S.B. A suggested approach to once-daily aminoglycoside dosing. Br. J. Clin. Pharmacol., 1995, 39(6), 605-609.
16. Steimer, W.; Muller, C.; Eber, B. Digoxin assays: frequent, substantial, and potentially dangerous interference by spironolactone, canrenone, and other steroids. Clin. Chem., 2002, 48(3), 507-516.
17. Somerville, A.L.; Wright, D.H.; Rotschafer, J.C. Implications of vancomycin degradation products on therapeutic drug monitoring in patients with end-stage renal disease. Pharmacotherapy, 1999, 19(6), 702-707.
18. Sheiner, L.B. The population approach to pharmacokinetic data analysis: rationale and standard data analysis methods. Drug Metab. Rev., 1984, 15(1-2), 153-171.
19. Walson, P.D. Therapeutic drug monitoring in special populations. Clin. Chem., 1998, 44(2), 415-419.
20. Rybak, M.J.; Lomaestro, B.M.; Rotschafer, J.C.; Moellering, R.C., Jr.; Craig, W.A.; Billeter, M.; Dalovisio, J.R.; Levine, D.P. Therapeutic monitoring of vancomycin in adults summary of consensus recommendations from the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists. Pharmacotherapy, 2009, 29(11), 1275-1279.
21. Roberts, J.A.; Hope, W.W.; Lipman, J. Therapeutic drug monitoring of beta-lactams for critically ill patients: unwarranted or essential? Int. J. Antimicrob. Agents, 2010, 35(5), 419-420.
22. Roberts, J.A.; Ulldemolins M.; Roberts, M.S.; McWhinney, B.C.; Ungerer, J.P.J.; Paterson, D.L.; Lipman, J. Therapeutic drug monitoring of beta-lactams in critically ill patients: proof of concept. Int. J. Antimicrob. Agents, 2010, 36(4), 332-339.
23. Joukhadar, C.; Muller, M. Microdialysis: current applications in clinical pharmacokinetic studies and its potential role in the future. Clin. Pharmacokinet, 2005, 44(9), 895-913.
24. de la Pena, A.; Liu, P.; Derendorf, H. Microdialysis in peripheral tissues. Adv. Drug Deliv. Rev., 2000, 45(2-3), 189-216.
25. Elmquist, W.F.; Sawchuk, R.J. Application of microdialysis in pharmacokinetic studies. Pharm. Res., 1997, 14(3), 267-288.
26. Brunner, M.; Derendorf, H.; Muller, M. Microdialysis for in vivo pharmacokinetic/pharmacodynamic characterization of antiinfective drugs. Curr. Opin. Pharmacol., 2005, 5(5), 495-499.
27. Buerger, C.; Plock, N.; Dehghanyar, P.; Joukhadar, C.; Kloft, C. Pharmacokinetics of unbound linezolid in plasma and tissue interstitium of critically ill patients after multiple dosing using microdialysis. Antimicrob. Agents Chemother., 2006, 50(7), 2455-2463.
28. Roberts, J.A.; Roberts, M.S.; Robertson, T.A.; Cross, S.E. Lipman, J. A novel way to investigate the effects of plasma exchange on antibiotic levels: use of microdialysis. Int. J. Antimicrob. Agents, 2008, 31(3), 240-244.
29. Joukhadar, C.; Frossard, M.; Mayer, B.X.; Brunner, M.; Klein, N.; Siostrzonek, P.; Eichler, H.G.; Muller, M. Impaired target site penetration of beta-lactams may account for therapeutic failure in patients with septic shock. Crit. Care Med., 2001, 29(2), 385-391.
30. Brunner, M.; Pernerstorfer, T.; Mayer, B.X.; Eichler, H.G.; Muller, M. Surgery and intensive care procedures affect the target site distribution of piperacillin. Crit. Care Med., 2000, 28(6), 1754-1759.
31. Gosling, P.; Sanghera, K.; Dickson, G. Generalized vascular permeability and pulmonary function in patients following serious trauma. J. Trauma., 1994, 36(4), 477-481.
32. Nuytinck, H.K.; Offermans, X.J.; Kubat, K.; Goris, J.A. Wholebody inflammation in trauma patients. An autopsy study. Arch. Surg., 1988, 123(12), 1519-1524.
33. Dasta, J.F.; Armstrong, D.K. Variability in aminoglycoside pharmacokinetics in critically ill surgical patients. Crit. Care Med., 1988, 16(4), 327-330.
34. Oparaoji, E.C.; Cornwell, E.E 3rd.; Hekmat, E.; Lum Cheong, R.; Adir, J.S.; Siram, S. Aminoglycoside volume of distribution in postoperative patients with septic shock. Clin. Pharm., 1993, 12(2), 131-134.
35. Zdolsek, H.J.; Lisander, B.; Jones, A.W.; Sjoberg, F. Albumin supplementation during the first week after a burn does not mobilise tissue oedema in humans. Intensive Care Med., 2001, 27(5), 844-852.
36. Buchholz, A.C.; Bartok, C.; Schoeller, D.A. The validity of bioelectrical impedance models in clinical populations. Nutr. Clin. Pract., 2004, 19(5), 433-446.
37. Heymsfield, S.B.; Wang, Z.; Visser, M.; Gallagher, D. and Pierson, R.N., Jr. Techniques used in the measurement of body composition: an overview with emphasis on bioelectrical impedance analysis. Am. J. Clin. Nutr., 1996, 64(3 Suppl), 478S-484S.
38. Kyle, U.G.; Bosaeus, I.; De Lorenzo, A.D.; Deurenberg, P.; Elia, M.; Gomez, J.M.; Heitmann, B.L.; Kent-Smith, L.; Melchior, J.C.; Pirlich, M.; Scharfetter, H.; Schols, A.M.; Pichard, C. Bioelectrical impedance analysis--part I: review of principles and methods. Clin. Nutr., 2004, 23(5), 1226-1243.
39. Kyle, U.G.; Bosaeus, I.; De Lorenzo, A.D.; Deurenberg, P.; Elia, M.; Manuel Gomez, J.; Lilienthal Heitmann, B.; Kent-Smith, L.; Melchior, J.C.; Pirlich, M.; Scharfetter, H.; Schols, A.M.; Pichard, C. Bioelectrical impedance analysis-part II: utilization in clinical practice. Clin. Nutr., 2004, 23(6), 1430-1453.
40. Finn, P.J.; Plank, L.D.; Clark, M.A.; Connolly, A.B.; Hill, G.L. Progressive cellular dehydration and proteolysis in critically ill patients. Lancet, 1996, 347(9002), 654-656.
41. Plank, L.D.; Monk, D.N.; Woollard, G.A.; Hill, G. L. Evaluation of multifrequency bioimpedance spectroscopy for measurement of the extracellular water space in critically ill patients. Appl. Radiat. Isot., 1998, 49(5-6), 481-483.
42. Baarends, E.M.; van Marken Lichtenbelt, W.D.; Wouters, E.F.; Schols, A.M. Body-water compartments measured by bio-electrical impedance spectroscopy in patients with chronic obstructive pulmonary disease. Clin. Nutr., 1998, 17(1), 15-22
43. Hannan, W.J.; Cowen, S.J.; Plester, C.E.; Fearon, K.C.; deBeau, A. Comparison of bio-impedance spectroscopy and multi-frequency bio-impedance analysis for the assessment of extracellular and total body water in surgical patients. Clin. Sci., (Lond). 1995, 89(6), 651-658.
44. Simpson, J.A.; Lobo, D.N.; Anderson, J.A.; Macdonald, I.A.; Perkins, A.C.; Neal, K.R.; Allison, S.P.; Rowlands, B.J. Body water compartment measurements: a comparison of bioelectrical impedance analysis with tritium and sodium bromide dilution techniques. Clin. Nutr., 2001, 20(4), 339-343.
45. Jacob, M.; Conzen, P.; Finsterer, U.; Krafft, A.; Becker, B.F.; Rehm, M. Technical and physiological background of plasma volume measurement with indocyanine green: a clarification of misunderstandings. J. Appl. Physiol., 2007, 102(3), 1235-1242.
46. Baulig, W.; Bernhard, E. O.; Bettex, D.; Schmidlin, D.; Schmid, E.R. Cardiac output measurement by pulse dye densitometry in cardiac surgery. Anaesthesia, 2005, 60(10), 968-973.
47. Caesar, J.; Shaldon, S.; Chiandussi, L.; Guevara, L.; Sherlock, S. The use of indocyanine green in the measurement ofhepatic blood flow and as a test of hepatic function. Clin. Sci., 1961, 21, 43-57.
48. Sakka, S. G.; Reinhart, K. and Meier-Hellmann, A. Intensive Care Med., 2000, 26(10), 1553-1556.
49. Faybik, P.; Krenn, C.G.; Baker, A.; Lahner, D.; Berlakovich, G.; Steltzer, H.; Hetz, H. Comparison of invasive and noninvasive measurement of plasma disappearance rate of indocyanine green in patients undergoing liver transplantation: a prospective investigator- blinded study. Liver Transpl., 2004, 10(8), 1060-1064.
50. Purcell, R.; Kruger, P.; Jones M. Indocyanine green elimination: a comparison of the LiMON and serial blood sampling methods. ANZ J. Surg., 2006, 76(1-2), 75-77.
51. Luce, J.M.; Cook, D.J.; Martin, T.R.; Angus, D.C.; Boushey, H.A.; Curtis, J.R.; Heffner, J.E.; Lanken, P.N.; Levy, M.M.; Polite, P.Y.; Rocker, G.M.; Truog, R.D. The ethical conduct of clinical research involving critically ill patients in the United States and Canada: principles and recommendations. Am. J. Respir. Crit. Care Med., 2004, 170(12), 1375-1384.